Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Disease and Thrombocytopenia

NCT02227693 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT02227693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02227693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Disease and Thrombocytopenia
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2014
Completion date
April 1, 2015
Enrollment
39 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopenia associated with chronic liver disease